Literature DB >> 34904797

CAR T-Cell Therapy for Large B-Cell Lymphoma - Who, When, and How?

Mark Roschewski1, Dan L Longo1, Wyndham H Wilson1.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2021        PMID： 34904797      PMCID： PMC9295142          DOI： 10.1056/NEJMe2118899

Source DB:  PubMed          Journal:  N Engl J Med        ISSN： 0028-4793            Impact factor:   176.079


× No keyword cloud information.
  8 in total

1.  Tisagenlecleucel in Adult Relapsed or Refractory Diffuse Large B-Cell Lymphoma.

Authors:  Stephen J Schuster; Michael R Bishop; Constantine S Tam; Edmund K Waller; Peter Borchmann; Joseph P McGuirk; Ulrich Jäger; Samantha Jaglowski; Charalambos Andreadis; Jason R Westin; Isabelle Fleury; Veronika Bachanova; S Ronan Foley; P Joy Ho; Stephan Mielke; John M Magenau; Harald Holte; Serafino Pantano; Lida B Pacaud; Rakesh Awasthi; Jufen Chu; Özlem Anak; Gilles Salles; Richard T Maziarz
Journal:  N Engl J Med       Date:  2018-12-01       Impact factor: 91.245

2.  Long-term safety and activity of axicabtagene ciloleucel in refractory large B-cell lymphoma (ZUMA-1): a single-arm, multicentre, phase 1-2 trial.

Authors:  Frederick L Locke; Armin Ghobadi; Caron A Jacobson; David B Miklos; Lazaros J Lekakis; Olalekan O Oluwole; Yi Lin; Ira Braunschweig; Brian T Hill; John M Timmerman; Abhinav Deol; Patrick M Reagan; Patrick Stiff; Ian W Flinn; Umar Farooq; Andre Goy; Peter A McSweeney; Javier Munoz; Tanya Siddiqi; Julio C Chavez; Alex F Herrera; Nancy L Bartlett; Jeffrey S Wiezorek; Lynn Navale; Allen Xue; Yizhou Jiang; Adrian Bot; John M Rossi; Jenny J Kim; William Y Go; Sattva S Neelapu
Journal:  Lancet Oncol       Date:  2018-12-02       Impact factor: 41.316

3.  Lisocabtagene maraleucel for patients with relapsed or refractory large B-cell lymphomas (TRANSCEND NHL 001): a multicentre seamless design study.

Authors:  Jeremy S Abramson; M Lia Palomba; Leo I Gordon; Matthew A Lunning; Michael Wang; Jon Arnason; Amitkumar Mehta; Enkhtsetseg Purev; David G Maloney; Charalambos Andreadis; Alison Sehgal; Scott R Solomon; Nilanjan Ghosh; Tina M Albertson; Jacob Garcia; Ana Kostic; Mary Mallaney; Ken Ogasawara; Kathryn Newhall; Yeonhee Kim; Daniel Li; Tanya Siddiqi
Journal:  Lancet       Date:  2020-09-01       Impact factor: 79.321

4.  Axicabtagene Ciloleucel CAR T-Cell Therapy in Refractory Large B-Cell Lymphoma.

Authors:  Sattva S Neelapu; Frederick L Locke; Nancy L Bartlett; Lazaros J Lekakis; David B Miklos; Caron A Jacobson; Ira Braunschweig; Olalekan O Oluwole; Tanya Siddiqi; Yi Lin; John M Timmerman; Patrick J Stiff; Jonathan W Friedberg; Ian W Flinn; Andre Goy; Brian T Hill; Mitchell R Smith; Abhinav Deol; Umar Farooq; Peter McSweeney; Javier Munoz; Irit Avivi; Januario E Castro; Jason R Westin; Julio C Chavez; Armin Ghobadi; Krishna V Komanduri; Ronald Levy; Eric D Jacobsen; Thomas E Witzig; Patrick Reagan; Adrian Bot; John Rossi; Lynn Navale; Yizhou Jiang; Jeff Aycock; Meg Elias; David Chang; Jeff Wiezorek; William Y Go
Journal:  N Engl J Med       Date:  2017-12-10       Impact factor: 91.245

5.  Salvage regimens with autologous transplantation for relapsed large B-cell lymphoma in the rituximab era.

Authors:  Christian Gisselbrecht; Bertram Glass; Nicolas Mounier; Devinder Singh Gill; David C Linch; Marek Trneny; Andre Bosly; Nicolas Ketterer; Ofer Shpilberg; Hans Hagberg; David Ma; Josette Brière; Craig H Moskowitz; Norbert Schmitz
Journal:  J Clin Oncol       Date:  2010-07-26       Impact factor: 44.544

6.  Genetics and Pathogenesis of Diffuse Large B-Cell Lymphoma.

Authors:  Roland Schmitz; George W Wright; Da Wei Huang; Calvin A Johnson; James D Phelan; James Q Wang; Sandrine Roulland; Monica Kasbekar; Ryan M Young; Arthur L Shaffer; Daniel J Hodson; Wenming Xiao; Xin Yu; Yandan Yang; Hong Zhao; Weihong Xu; Xuelu Liu; Bin Zhou; Wei Du; Wing C Chan; Elaine S Jaffe; Randy D Gascoyne; Joseph M Connors; Elias Campo; Armando Lopez-Guillermo; Andreas Rosenwald; German Ott; Jan Delabie; Lisa M Rimsza; Kevin Tay Kuang Wei; Andrew D Zelenetz; John P Leonard; Nancy L Bartlett; Bao Tran; Jyoti Shetty; Yongmei Zhao; Dan R Soppet; Stefania Pittaluga; Wyndham H Wilson; Louis M Staudt
Journal:  N Engl J Med       Date:  2018-04-12       Impact factor: 91.245

7.  Bridging therapy prior to axicabtagene ciloleucel for relapsed/refractory large B-cell lymphoma.

Authors:  Chelsea C Pinnix; Jillian R Gunther; Bouthaina S Dabaja; Paolo Strati; Penny Fang; Misha C Hawkins; Sherry Adkins; Jason Westin; Sairah Ahmed; Luis Fayad; Hun Ju Lee; Ranjit Nair; Raphael E Steiner; Swaminathan P Iyer; M Alma Rodriguez; Michael Wang; Christopher Flowers; Sattva S Neelapu; Loretta J Nastoupil
Journal:  Blood Adv       Date:  2020-07-14
  8 in total
  8 in total

Review 1.  Clinical trials for chimeric antigen receptor T-cell therapy: lessons learned and future directions.

Authors:  Brett A Schroeder; Jennifer Jess; Hari Sankaran; Nirali N Shah
Journal:  Curr Opin Hematol       Date:  2022-07-01       Impact factor: 3.218

2.  BeEAM High-Dose Chemotherapy with Polatuzumab (Pola-BeEAM) before ASCT in Patients with DLBCL-A Pilot Study.

Authors:  Tanja Stoffel; Ulrike Bacher; Yara Banz; Michael Daskalakis; Urban Novak; Thomas Pabst
Journal:  J Clin Med       Date:  2022-06-28       Impact factor: 4.964

3.  Current state and future opportunities in granulocyte colony-stimulating factor (G-CSF).

Authors:  Hartmut Link
Journal:  Support Care Cancer       Date:  2022-09       Impact factor: 3.359

Review 4.  Influence of Culture Conditions on Ex Vivo Expansion of T Lymphocytes and Their Function for Therapy: Current Insights and Open Questions.

Authors:  Harish Sudarsanam; Raymund Buhmann; Reinhard Henschler
Journal:  Front Bioeng Biotechnol       Date:  2022-06-29

5.  Toxicities and Response Rates of Secondary CNS Lymphoma After Adoptive Immunotherapy With CD19-Directed Chimeric Antigen Receptor T Cells.

Authors:  Philipp Karschnia; Kai Rejeski; Michael Winkelmann; Florian Schöberl; Veit L Bücklein; Viktoria Blumenberg; Christian Schmidt; Jens Blobner; Michael von Bergwelt-Baildon; Joerg-Christian Tonn; Wolfgang G Kunz; Marion Subklewe; Louisa von Baumgarten
Journal:  Neurology       Date:  2022-03-29       Impact factor: 11.800

Review 6.  Engineered Microphysiological Systems for Testing Effectiveness of Cell-Based Cancer Immunotherapies.

Authors:  Marco Campisi; Sarah E Shelton; Minyue Chen; Roger D Kamm; David A Barbie; Erik H Knelson
Journal:  Cancers (Basel)       Date:  2022-07-22       Impact factor: 6.575

7.  Transgenic expression of IL-7 regulates CAR-T cell metabolism and enhances in vivo persistence against tumor cells.

Authors:  Li Li; Qing Li; Zi-Xun Yan; Ling-Shuang Sheng; Di Fu; Pengpeng Xu; Li Wang; Wei-Li Zhao
Journal:  Sci Rep       Date:  2022-07-22       Impact factor: 4.996

Review 8.  Current options and future perspectives in the treatment of patients with relapsed/refractory diffuse large B-cell lymphoma.

Authors:  Fabian Frontzek; Imke Karsten; Norbert Schmitz; Georg Lenz
Journal:  Ther Adv Hematol       Date:  2022-06-28
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.